SPRED2 and chronic myelogenous leukemia, BCR-ABL1 positive: Our results showed that imatinib or Spred2 over-expression could increase the CD235a and GATA1 expression, while the combination of imatinib and Spred2 over-expression was much more impressive (Fig. 4B–4E), suggesting the combination might be a potential strategy for CML therapy.